Medscape (8/10, Brooks, Subscription Publication) reports new research shows that “one of the two major psychoactive constituents in kratom has high abuse potential and may also increase the intake of other opiates.” The finding “contradicts claims by kratom makers that the substance has no abuse potential and supports the US Food and Drug Administration’s (FDA’s) view that kratom is an opioid.” Mitragynine (MG) and 7-hydroxymitragynine (7-HMG) “are the two major psychoactive constituents of kratom,” and the researchers wrote 7-HMG should be considered a kratom constituent with “high abuse potential that may also increase the intake of other opiates.” The study was published online June 27 in Addiction Biology.
Related Links:
— Medscape (requires login and subscription)